Willingness to Pay for a Treatment for Pain in Multiple Sclerosis

Background: Multiple sclerosis (MS) is a chronic neurological disease that affects 240 per 100 000 Canadians. Of these patients, 10–80% (average 70%) experience pain. Sativex® is a cannabis-based drug recently approved for neuropathic pain.